Achieve Life Sciences (ACHV) Total Non-Current Liabilities (2010 - 2026)

Achieve Life Sciences' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $21.2 million for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 33.56% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 33.56% YoY) and the FY2025 annual result came in at $18.7 million, up 12.84% from the prior year.
• Total Non-Current Liabilities was $21.2 million for Q1 2026 at Achieve Life Sciences, up from $18.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $21.9 million in Q2 2024 and bottomed at $15.8 million in Q1 2025.
• A 4-year average of $18.6 million and a median of $18.6 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2025 — Total Non-Current Liabilities declined 21.04% — and 2026, when it jumped 33.56%.
• Achieve Life Sciences' Total Non-Current Liabilities stood at $20.3 million in 2023, then slipped by 18.26% to $16.6 million in 2024, then gained by 12.84% to $18.7 million in 2025, then rose by 13.04% to $21.2 million in 2026.
• Business Quant data shows ACHV's Total Non-Current Liabilities at $21.2 million in Q1 2026, $18.7 million in Q4 2025, and $18.4 million in Q3 2025.